We met with Dr. Alok Khorana in Berlin during the ISTH 2017 Congress. He could not hide his enthusiasm about the discoveries of the Vienna group and about two trials using his Khorana risk score: the Cassini study, co-chaired with Prof. Lyman, and the AVERT study, also led by Marc Carrier and Phil Wells. Both of them include patients with a > 2 risk score, which he believes they will constitute a big step forward in knowledge for prevention of CAT.
As per treatment of CAT goes, he looks forward to hearing the results of HOKUSAI (edoxaban vs warfarin) and SELECT-D (rivaroxaban vs LWMH) trial.
Hear his own words!